Re:Cognition Health is enrolling volunteers to participate in studies.

Current Studies

The Green Memory Study (Phase III)

The Green Memory study is researching an investigational medication designed to rebalance certain bacteria in the gut, as previous research has shown an imbalance in gut bacteria could be linked to Alzheimer’s and other diseases. The investigational medication has been researched and approved in other countries, where it was proven to be safe and effective. The investigational medication works to rebalance good gut bacteria, reducing brain inflammation and effects relevant to AD.

You can learn more about the Green Memory Study at the following link or the video below: https://www.greenmemoryalzstudy.com/

You or a loved one may participate in the Green Memory Study if you/they:

  • Are 50-85 years of age
  • Have mild to moderate AD
  • Have a study partner who knows the participant well and can come to all study-related visits and is with them 3 or more days a week

The FOUND Study (Phase III)

The FOUND study is researching the effect of the oral drug fasudil which may improve blood flow in the brain and improve memory pertaining to location and navigation. The purpose of the FOUND study is to help learn whether fasudil reduces wandering in subjects with dementia. The study will also assess effects of fasudil on thinking, memory, emotional symptoms, and caregiver/nursing staff burden, as well as how well fasudil is tolerated and how safe it is.

You or a loved one may participate in the FOUND Study if you/they:

  • 50 to 90 years of age 
  • Diagnosis of dementia of any etiology
  • Presence of one or both of the following wandering behaviors of at least of moderate severity:
    • Elopes or attempts to elope
    • Gets lost or is unable to locate a specific place
  • Has a caregiver who has more than 10 hours/week of contact with the subject who is fluent in English and is willing to accept responsibility for supervising the treatment and assessing the condition of the subject throughout the study

Not sure if you qualify? Register and we’ll reach out to you to find out.

 

The Aspect Study

In this study, researchers want to find out if an investigational drug called AVP-786 is safe and effective (useful) in managing agitation in adults with Alzheimer’s dementia, when compared to a placebo. To be eligible for this study, a potential participant must:

  • Be between the ages of 50 and 90
  • Have a diagnosis of probable Alzheimer’s disease
  • Have moderate-to-severe agitation that interferes with daily life

The CVL-871-2001 Study

Do you, or someone you care for, have dementia? Have you/they lost interest in everyday life?

The CVL-871-2001 Study is looking at how safe an investigational medication is in people with dementia-related apathy and how it may work in the body. Apathy is a loss of interest in everyday life and lack of motivation. It is often a forgotten symptom of dementia.
You, or someone you care for, may be able to take part if you/they:

  • Are 50–85 years of age
  • Have been diagnosed with dementia
  • Have dementia-related apathy

You can learn more about the CVL-871-2001 Study at the following link: CVL-871 – Cerevel Therapeutics

 

The SIGNAL – AD Study

SIGNAL-AD is a clinical study of an investigational drug called Pepinemab. The study will evaluate the drug’s safety profile, brain imaging effects and potential effects on cognition in people with early Alzheimer’s disease (AD). Study assessments, testing and medication are provided at no cost to participants. Some people may receive stipends for participation.

  • Are 55 to 85 years old Have evidence of Mild Cognitive Impairment
  • Probable AD or mild-AD.
  • Have a partner who will support you and participate in the study

The Together Study

The study is part of a global effort to find better choices for treatment in the future for people with early memory loss and for those with early Alzheimer’s disease. The purpose of the study is to investigate the effect of bepranemab versus (vs) placebo on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) up to Week 80 in study participants with prodromal or mild Alzheimer’s Disease (AD).

  • Age range 50-80
  • A diagnosis of prodromal/mild cognitive impairment (MCI) due to Alzheimer’s Disease (AD) or mild AD according to National Institute of Aging-Alzheimer’s Association (NIA-AA)

Interest Form

  • Submit your interest to our team of specialists

  • Date Format: MM slash DD slash YYYY